Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Up to 5,000 now. Still accumulating
Added another 993 today bringing total to 4,500. Still accumulating
Seatbelts!!! We r going to take this one up
He called bottom on $INPX Thursday. And then Friday after hours, BOOM!!!
I also expect $NTEC boom, anytime soon.
Too bad he didn't say if he was going to buy or sell, just do the opposite and you will make money every time! Instead puts up a chart video a 5 year old can figure out on his own. I will actually watch it if it is a stock I own or think of buying, saves me time. The dude can't trade though, that is for dam sure!
possible base here between .37/.41? still good vol on the up days, on watch list.
I just got done with a multi monthly hold on genius. Letting that super gain soak in
Roger that: Holding on here;) maybe check out tptw;good DD now at bottom .018!!
Should spike soon; did well on last run..Likely you’re on it $$$
GL..
Gaytrader is here is why it's silent. Fireworks soon in my opinion.
Yup Gone again!!
and it's gone again, nice.
Not many recent posts here
Likely Building higher base:))
Possibly up trend coming soon
* * $NTEC Video Chart 06-01-2020 * *
Link to Video - click here to watch the technical chart video
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the first quarter ended March 31, 2020 and provides a corporate update.
Highlights from the Quarter and Recent Weeks
-- Announced that the Accordion Pill (AP) developed for a Merck & Co. (MSD) proprietary compound met the in vitro specifications set forth in the companies' research collaboration and the Company is now in discussions with MSD regarding advancing the program into the clinic;
-- Enhanced the balance sheet with a $6.5 million public offering in February 2020 and with a $5 million registered direct offering in May 2020;
-- Received a $1.5 million payment from Novartis related to the conclusion of the Feasibility Option Agreement the Company had with Novartis;
-- Initiated AP-Carbidopa/Levodopa (AP CD/LD) commercial manufacturing stability lots with LTS Lohmann Therapie-Systeme AG (LTS);
-- Completed the redesign of AP-Tetrahydrocannabinol (AP-THC) and are awaiting delivery of synthetic THC to initiate clinical material production; and
-- Initiated next generation AP technologies to include longer retention times (e.g. 24 hour gastric retention) as well as larger molecules (e.g. peptides).
Management Commentary
"We continue to build the company's scientific and technical expertise in oral drug delivery and drug-on-film technologies. Our research and manufacturing teams continue to drive innovation as we expand our capabilities and build out our portfolio of potential applications," stated Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma.
"In collaboration with our partner, LTS, we demonstrated our ability to manufacture at commercial scale. This proficiency, coupled with our recent successes in developing unique APs to meet the technical specifications set forth by Novartis and Merck, enhances our ability to engage in partnership discussions with other large biopharma companies as we actively seek to add more collaborative agreements in 2020.
"""""Our partnering activities for the AP-CD/LD program in Parkinson's disease continue and there remain multiple parties with interest in this program. Unfortunately, this has not progressed to an agreement and believe this is related to certain commercialization concerns as well as to the overall market environment as a result of the COVID-19 pandemic. In addition, we continue our discussions with Merck with an aim to advance that program into human pharmacokinetic (PK) trials.""""
"We are delighted to report the completion of a new AP design for our AP-THC program that we expect will meet our stringent PK specifications. We are currently awaiting receipt of the active pharmaceutical ingredients so we can initiate clinical material production and, hopefully, advance this program into the clinic later this year.
39,000 shares but whatever. Don't think this is going anywhere soon but you never know.
I sold in pre-market all my 30,000 shares for .30 It took 11 minutes to get filled but I am so glad I did! Check out EVFM, that's what I am in now. It will explode tomorrow!
Removing ask after others sell below...
I put up 10,000 shares @ .0273 ask,,, will remove it after go to bathroom
What’s the real expectation here?...
Just building on PR?... or is there something more substantial coming?
Just a matter of time.
NTEC
I think we will, but it’s Friday before a long weekend otherwise we will close green .
Loaded here the last couple of trading days.....think we see a nice pop.
NTEC
* * $NTEC Video Chart 05-22-2020 * *
Link to Video - click here to watch the technical chart video
* * $NTEC Video Chart 05-21-2020 * *
Link to Video - click here to watch the technical chart video
Yes! I helped bust through that .24.
Intec Pharma Announces $5.0 Million Registered Direct Offering
3:33 pm ET May 4, 2020 (Globe Newswire) Print
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company"), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 16,291,952 of the Company's ordinary shares, at a purchase price of $0.30690 per share, in a registered direct offering. Intec has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 8,145,976 ordinary shares. The offering is expected to close on or about May 6, 2020, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The warrants will have a term of five and one-half years, be exercisable immediately and have an exercise price of $0.245 per ordinary share.
The gross proceeds to Intec from this offering are expected to be approximately $5.0 million, before deducting the placement agent's fees and other offering expenses. The Company intends to use the net proceeds from the offering to fund its research and development activities and for working capital and general corporate purposes.
The ordinary shares (but not the warrants or the ordinary shares underlying the warrants) are being offered by Intec pursuant to a "shelf" registration statement on Form S-3 (File No. 333-230016) previously filed with the Securities and Exchange Commission (the "SEC") on March 1, 2019 and declared effective by the SEC on March 28, 2019. The offering of the ordinary shares will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the ordinary shares being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at
* * $NTEC Video Chart 05-04-2020 * *
Link to Video - click here to watch the technical chart video
Intec Pharma Ltd. (NTEC): This clinical stage biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 45.9% over the last 60 days.
agreed, new HOD $.349 so far...
$NTEC looking interesting
Followers
|
37
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
696
|
Created
|
10/17/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |